Auvelity: Understanding Mechanism of Action

On Aug 19, 2022 Axsome Therapeutics announced the FDA Approval of Auvelity, as the first and Only Oral NMDA Receptor Antagonist for the treatment of Major Depressive Disorder in adults.
This video will summarize the mechanism of action of this novel antidepressant.
Read blog post here: psychiatryeducationforum.com/...